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Background: Hypertension is common in older cats. There is limited evidence for predictors of
survival after diagnosis.
Hypothesis/Objectives: Investigate blood pressure assessment (BPA) and hypertension diagno-
sis in cats attending UK primary care practices (PCPs) and factors that influence survival.
Animals: Cats (347 889) attending 244 UK PCPs enrolled in the VetCompass program between
January 1, 2012, and December 31, 2013. Cats identified as hypertensive (282) were included
in descriptive and survival analyses.
Methods: All electronic patient records (EPRs) were searched to identify cats that potentially
had received BPA. EPRs were read in detail to identify those that had BPA. The proportion that
received BPA was evaluated using a stratified analysis and the incidence of hypertension
estimated. A retrospective cohort study was used to investigate survival after diagnosis (Cox
proportional hazard model).
Results: Estimated incidence risk was 19.5% (95% confidence interval [CI], 17.5-21.6) from the
estimated 1.34% (1.30%-1.38%) of cats that received BPA. Few cats had BPA more than once
after diagnosis (median, 1; interquartile range [IQR], 0-3), with only 9.9% of diagnosed hyperten-
sive cats having urine protein:creatinine ratio determined. Cats diagnosed as a result of monitor-
ing of pre-existing disease had improved survival (hazard ratio [HR], 0.58; 95% CI, 0.37-0.89;
P = .01) compared to cats diagnosed after clinical signs were recognized. Cats that had an
amlodipine dose change had improved survival (HR, 0.56; 95% CI, 0.36-0.87; P = .01) compared
to those with no dose change.
Conclusions and clinical importance: These data suggest improved blood pressure monitoring in
clinical practice may decrease the morbidity associated with hypertension.
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1 | INTRODUCTION
Hypertension is a common disease in older cats, with up to 13% of
healthy cats ≥9 years of age being diagnosed with hypertension.1–3
This frequency increases to 87% in studies in which cats have concur-
rent disease.2,4,5 Previous prevalence estimates are difficult to com-
pare because of variation in case definition of hypertension. The
American College of Veterinary Internal Medicine (ACVIM) guidelines
and the International Renal Interest Society (IRIS) staging system have
attempted to standardize the definition of hypertension by categoriz-
ing blood pressure based on estimated risk of target organ damage
(TOD). A systolic blood pressure (SBP) <150 mm Hg is considered
normotensive (minimal risk), a SBP of 150-159 mm Hg is considered
Abbreviations: ACVIM, American College of Veterinary Internal Medicine; AIC,
Akaike information criterion; BIC, Bayesian information criterion; CI, confidence
interval; CKD, chronic kidney disease; EPR, electronic patient record; HR, haz-
ard ratio; IQR, interquartile range; IRIS, International Renal Interest Society;
LRT, likelihood ratio test; QOL, quality of life; TOD, target organ damage; UK,
United Kingdom; UPC, urine protein:creatinine ratio
Received: 19 March 2017 Revised: 28 April 2018 Accepted: 24 July 2018
DOI: 10.1111/jvim.15307
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes. © 2018 The Authors. Journal of Veterinary Internal Medicine published
by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
J Vet Intern Med. 2018;1–10. wileyonlinelibrary.com/journal/jvim 1
borderline hypertensive (low risk), a SBP of 160-179 mm Hg is consid-
ered hypertensive (moderate risk) and a SPB ≥ 180 mm Hg is consid-
ered severely hypertensive (severe risk).6,7 Hypertension in cats
frequently is associated with an underlying disease, with chronic kid-
ney disease (CKD) and hyperthyroidism most commonly
reported.2,4,8,9 Idiopathic hypertension is estimated to occur in up to
20% of cases.10,11 The aim of identifying hypertension early is to
decrease the risk of TOD.6 Target organ damage can occur in the
brain,12 eyes,13 heart,12 or kidneys6 with ocular TOD most easily
recognized in association with hypertension in general practice. Target
organ damage is associated with considerable morbidity, including
blindness, ventricular hypertrophy, proteinuria, and hypertensive
encephalopathy.5,13,14 Amlodipine, a calcium channel blocker, is
recommended for the treatment of hypertension6,7 and has been
found to be effective at decreasing blood pressure in hypertensive
cats.8,15,16
Limited research has been done into survival after diagnosis of
hypertension in cats that are presented to primary care practice (PCP)
in the United Kingdom (UK). Median survival time previously has been
estimated to be up to 490 days in cats that were not proteinuric at
diagnosis, whereas median survival time has been estimated to be
162 days in cats that were proteinuric at diagnosis.8 Urine protein:
creatinine ratio (UPC) has been found to be correlated with decreased
survival when adjusted for IRIS stage, both when assessed at initial
diagnosis and as the time-averaged UPC while on treatment.8 Much
of the published data however derive from a small number of prac-
tices and referral centers where specific screening as well as diagnos-
tic and treatment protocols tend to be followed. Thus, there is a
deficiency of information on hypertension that is diagnosed in cats
presented to PCP in the UK and how these cats are managed by gen-
eral practitioners. The use of data from electronic patient records
(EPRs) allows epidemiological studies on a large dataset that can be
generalized to the cat population presented to PCP in the UK. The
aims of our study were to estimate the proportion of cats in the UK
receiving blood pressure assessment (BPA), describe cats diagnosed
with hypertension, and investigate survival after diagnosis of hyper-
tension in cats presented to PCP in the UK.
2 | MATERIALS AND METHODS
The Veterinary Companion Animal Surveillance System (VetCompass)17
project collects and collates anonymized EPR data from primary
care veterinary practices that have enrolled in the project. Patient
demographic data (species, breed, date of birth, sex, and body weight)
and clinical data (free clinical text, VeNom diagnosis terms,18 and treat-
ment fields) are uploaded in real time to the secure database where the
EPR can be accessed for epidemiological studies. Ethical approval for
the VetCompass project was provided by the Royal Veterinary College
Ethics and Welfare Committee and is supported by the Royal College
of Veterinary Surgeons.17 This study was approved by the Royal
Veterinary College Clinical Research Ethical Review Board (URN
M2015 0051).
The cohort of cats presented to VetCompass practices during the
study period was used to identify cats that received BPA and those
diagnosed with hypertension. A retrospective cohort study was used
to explore survival after hypertension diagnosis in cats. All cats
attending 244 primary care clinics enrolled in the VetCompass pro-
gram from January 1, 2012, to December 31, 2013, were included in
the study. The EPR was searched using VeNom diagnosis codes
(hypertensive disorder, hypertension, retinal separation/detachment,
blindness, retinal haemorrhage, and high blood pressure), clinical free
text terms (hyperten*, BP, blood pressure, blind*, retin* detach*,
hyphaema~1, retin* haem*~1, and amlod*), and treatments (amlod*,
istin, and blood pressure) associated with blood pressure measurement
and hypertension diagnosis. The results from the searches were
merged and duplicates removed. A random sample of 30.5% of these
potential cases was reviewed in detail to confirm BPA and hyperten-
sion diagnosis. A cat was considered to have had its blood pressure
assessed if a blood pressure measurement was recorded in the EPR or
the veterinarian considered the cat normotensive or hypertensive
after ocular examination. A cat was considered hypertensive if a diag-
nosis of hypertension was made in the EPR or a blood pressure mea-
surement was recorded in the EPR and antihypertensive medication
was started afterward. Demographic data were extracted automati-
cally and additional data (date of diagnosis, reason for presentation, date
of death, method of death, reason for death, blood pressure at all mea-
surements, number of blood pressure measurements, ocular exam, clinical
signs, goitre palpation, thoracic auscultation, urine protein measurement,
treatments, and co-morbidities) were collected manually from the EPR
of hypertensive cats. Data were exported to commercially available
software (Microsoft Excel 13) for checking and cleaning and then to
statistical software (Stata 11, StataCorp LP, College Station, Texas) for
statistical analysis.
Sample size calculations indicated that 212 hypertensive cats
would be required to detect an all-cause mortality hazard ratio (HR) of
0.5 for a variable to which 75% of cats were exposed (eg, amlodipine
use) with a power of 80% and 95% confidence, assuming, on average,
365 days of follow-up.19
2.1 | Statistical Analysis
For the calculations of proportion of cats that received BPA and the
incidence risk of hypertension, age was categorized as <9 years and
≥9 years or as <4.5 years, 4.5 to <9 years, 9 to <13.5 years, 13.5 to
<18 years, 18 to <22.5 years and ≥22.5 years. Reason for presenta-
tion at time of BPA was categorized as for: owner-reported clinical
signs (any clinical signs), anesthetic monitoring, geriatric health check,
monitoring of pre-existing disease (typically CKD or hyperthyroidism),
monitoring of pre-existing hypertension, and others. Cats that had a
blood pressure measurement to monitor pre-existing hypertension
only were included in the calculations for the proportion of cats that
received a BPA.
For the survival analysis, median and interquartile range (IQR)
were calculated for all continuous variables. Age was categorized as
<9 and ≥9 years. Breed was categorized into crossbred and purebred,
where purebred cats had a breed name recognized by International
Cat Care.20 Blood pressure was categorized into quartiles and by
ACVIM guidelines risk ranges (for SBP: minimum risk <150 mm Hg,
mild risk 150-159 mm Hg, moderate risk 160-179 mm Hg, and severe
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risk ≥180 mm Hg). Number of blood pressure measurements after
diagnosis was categorized as 0, 1, and ≥2. The UPC was categorized
as ≤0.2, 0.21-0.39, and ≥0.4. Treatments prescribed were categorized
as no amlodipine or benazepril, amlodipine only, benazepril only, and
amlodipine and benazepril combined. Comparison of continuous vari-
ables among groups was performed using the Mann-Whitney test for
non-normally distributed variables and Student’s t test for normally
distributed variables.
A weighted stratified analysis was performed, using Stata survey
commands, to account for the sampling strategy when estimating the
proportion of cats that received BPA. Strata 1 consisted of cats that
had had their EPR read in detail (a random sample of 30.5% of cats
identified by the key word clinical free text and VeNom diagnosis
searches) and were ascribed a sampling weight of 1/30.5. Strata 2 con-
sisted of all the cats that were not identified when their EPR were
searched for terms associated with hypertension and blood pressure
measurement and were ascribed a sampling weight of 1/100
(Figure 1). The sampling weights corrected for the fact that not all cats
had their EPRs read in detail, allowing an estimate of the proportion
of cats that had their blood pressure assessed to be calculated.21
Only cats that were newly diagnosed during the study period
were included in the incidence calculations. Incidence of hypertension
was calculated as the proportion of all cats that had their blood pres-
sure assessed during the study period, and that were diagnosed as
hypertensive. Confidence intervals (CI) were calculated by Stata using
exact methods.22
Clinical notes were followed until December 31, 2015. All cats
with ≥7 days follow-up were included in the survival analysis. A
univariable Cox proportional hazard model was used to investigate
associations between variables and survival. Any variable broadly
associated (P < .2) with survival was taken forward to the multivari-
able analysis. A manual forward stepwise model construction
approach was used to build the multivariable model. Confounders
were assessed by examining changes to the HR > 10% when included
in the model. Biologically plausible interactions were assessed using
the likelihood ratio test. Collinearity of continuous predictors was
evaluated for by examining Pearson’s correlation. The proportional
hazard assumption was tested by examining the log cumulative hazard
plot and assessment of Schoenfeld residuals. Model fit was assessed
by examining Cox-Snell residuals, and competing models were
assessed using the Akaike information criterion and the Bayesian
information criterion. Predictive ability of the model was assessed
using Harrell’s C statistic, and outliers were evaluated using deviance
residuals.23 Statistical significance was set at the 5% level.
3 | RESULTS
3.1 | Blood pressure assessment
Of the 347 889 cats that were presented to 244 PCPs from January
1, 2012, to December 31, 2013, 8001 were identified as potentially
having had their blood pressure assessed in the searches and 2442
(30.5%) of these were reviewed in detail. Of cats for which clinical
notes were reviewed, 1445 (59.2%) had their blood pressure assessed
during the study period (Figure 1). This resulted in an estimated 1.34%
(95% CI, 1.30-1.38) of cats that received BPA during the study period.
FIGURE 1 Flowchart describing the electronic patient record (EPR) search, stratification process, and of the number of cases used for the
analyses
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This percentage increased to 4.4% (95% CI, 4.3-4.6) in cats ≥9 years.
Most cats (94.8%; 1370) were assessed using blood pressure mea-
surement. Seventy (4.8%) cats were predicted to be normotensive or
hypertensive by ocular examination alone and 5 (0.04%) on clinical
signs alone. The proportion of cats having their blood pressure
assessed increased with age. Presentation with clinical signs was the
most common reason for a cat to have its blood pressure assessed
(Table 1). Owners of further 0.50% (95% CI, 0.46-0.53) or 535 cats
were offered a blood pressure measurement during the study period
but declined.
3.2 | Incidence of hypertension
Of the 1445 cats identified that had their blood pressure assessed
during the study period (2 years), 282 cats were diagnosed as hyper-
tensive during the study period. This resulted in an estimated inci-
dence risk of 19.5% (95% CI, 17.5-21.6) over the study period.
Incidence increased with age and was higher in crossbred cats than in
purebred cats. Hypertension was most frequently diagnosed in cats
presented for evaluation of clinical signs (Table 2).
3.3 | Descriptive statistics
All further analysis was undertaken on the 282 incident cases of
hypertension. The median age at diagnosis of hypertension was
16 years (IQR, 14.6-17.5). Body weight within 1 month of diagnosis
was recorded in 27.7% (79) of cats. Median body weight within
1 month of diagnosis was 3.4 kg (IQR, 3.1-4.1). Sex was recorded in
99.7% (281) of cats and 51.6% (145) were female. Neuter status was
recorded in 63.1% (178) of cats and 88.2% (157) were neutered.
Breed was recorded in 98.9% (279) of cats and most (92.2%; 260)
were crossbred. Clinical signs accounted for 63.1% (178) of presenta-
tions when hypertension was diagnosed, with a further 31.2%
(88) being presented for monitoring of concurrent disease, 4.3%
(13) for geriatric health evaluations, and 1.1% (3) for anesthetic moni-
toring. Blood pressure was measured in 78.4% (221) of cats at diagno-
sis and was recorded in 75.2% (212) of EPRs. Median blood pressure
at diagnosis was 206 mm Hg (IQR, 190-230). Most cats (92.9%; 197)
were within the ACVIM severe risk category at diagnosis, with 6.1%
(14) within the moderate risk category and 0.9% (2) in the low risk cat-
egory at diagnosis of hypertension. Of the 61 (21.6%) cats that did
not have a blood pressure measurement as the basis for diagnosis of
hypertension, most (56; 91.8%) were diagnosed after an ocular exami-
nation that disclosed signs compatible with hypertensive ocular dam-
age. The remaining 5 cats were diagnosed based on the clinical signs
for which they presented (eg, sudden onset blindness, neurological
signs, and hyperthyroidism). The median number of blood pressure
measurements after hypertension diagnosis was 1 (IQR, 0-3). Ocular
examination was performed in 61.4% (173) of cats. Clinical assess-
ment of hypertensive cats and clinical signs of hypertension reported
at diagnosis are presented in Table 3. Amlodipine was the most com-
mon treatment prescribed (68.4%; 193). The most common initial
dose was 0.625 mg daily (50.6%; 90) with an additional 37.1% (66) of
TABLE 1 Proportion of all cats receiving blood pressure assessment
Variable N
Blood pressure
assessed
Proportion blood
pressure assesseda (%) 95% CIa
Overall 347 889 1445 1.34 1.30-1.38
Age (years) <9 254 698 300 0.38 0.34-0.28
≥9 80 025 1139 4.4 4.3-4.6
0 to <4.5 187 460 142 0.25 0.20-0.28
4.5 to <9 67 238 158 0.76 0.65-0.88
9 to <13.5 44 185 413 3.0 2.7-3.2
13.5 to <18 28 401 566 6.1 5.7-6.5
18 to <22.5 7054 155 6.6 5.7-7.6
≥22.5 385 5 4.0 0.6-7.4
Sex Male 165 360 702 13.6 13.6-14.1
Female 177 749 739 13.4 12.8-14.5
Neuter Entire 58 105 78 0.4 0.3-0.5
Neutered 249 002 1119 1.5 1.4-1.51
Breed Crossbred 309 233 1237 1.29 1.24-1.34
Purebred 35 059 201 1.84 1.60-2.09
Reason for presentation at
blood pressure assessmentb
Clinical signs 1445 471 32.6 30.2-35.0
Anaesthetic monitoring 1445 425 29.4 27.1-31.8
Geriatric health check 1445 40 2.8 1.9-3.6
Monitoring of pre-existing disease 1445 419 29.0 26.7-31.3
Other 1445 5 0.4 0.04-0.7
Monitoring of pre-existing hypertension 1445 85 5.9 4.7-7.1
Abbreviation: CI, confidence interval.
a Calculated using stratified analysis and Stata survey commands.
b Proportion of cats receiving blood pressure assessment presented because of each category. This group only includes the 1445 cats that had their blood
pressure assessed.
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cats started on 1.25 mg daily. A total of 43 (22.3%) cats receiving
amlodipine had a dose increase during their follow-up, with a median
time to dose change of 38 days from starting amlodipine (IQR,
14-156). Cats requiring a dose increase had higher blood pressure at
diagnosis (median, 235.7 mm Hg; IQR, 201.0-270.0) in comparison to
cats that did not (median, 209.3; IQR, 190.0-220.0; Mann-Whitney
P < .001). Median number of blood pressure measurements was
2 (IQR, 1-4) in cats not receiving a dose change and 4 (IQR, 3-6) in cats
receiving a dose change (Mann-Whitney P < .0001). Benazepril was
prescribed to 39.4% (111) of cats. The most frequent reason for bena-
zepril prescription in these cats was for blood pressure control
(46.0%; 51), other reasons being concurrent CKD (39.6%; 44),
practitioner-diagnosed cardiac disease (12.6%; 14), and protein-losing
nephropathy (1.8%; 2). Just over a quarter (28%; 79) of cats received
amlodipine and benazepril combined, with 11.4% (32) receiving bena-
zepril alone. Other treatments prescribed were propranolol (0.3%; 1),
atenolol (4.3%; 12), and enalapril (0.3%; 1). Just under a fifth (19.5%;
55) did not receive any treatment for their hypertension. Most of
these cats (83.6%; 46) were euthanized within 7 days of diagnosis.
Chronic kidney disease was the most common co-morbidity diag-
nosed before or at the same time as hypertension (46.1%). Hyperthy-
roidism was diagnosed in 24.5% of cats before or at the time of
hypertension diagnosis. Diabetes mellitus was diagnosed in 2.13% of
hypertensive cats, all diagnosed before hypertension diagnosis. Just
under a third (30.5%; 86) of hypertensive cats did not have a concur-
rent disease diagnosed (idiopathic hypertensive cats). Only 50%
(43) of these “idiopathic hypertensive” cats had investigations per-
formed at or after hypertension diagnosis.
TABLE 2 Incidence risk of hypertension diagnosis during study period
Variable N
Hypertension
diagnosed
Incidence risk of
hypertension (%) 95% CIa
Overall 1445 282 19.5 17.5-21.7
Age (years) <9 300 9 3.0 1.4-5.6
≥9 1139 270 23.7 21.3-26.3
0 to <4.5 142 1 0.7 0.02-3.9
4.5 to <9 158 8 5.1 2.2-9.7
9 to < 13.5 413 44 10.7 7.8-14.0
13.5 to <18 566 167 29.5 25.8-33.5
18 to <22.5 155 56 36.1 28.6-44.2
22.5+ 5 3 60.0 14.7-94.7
Sex Male 702 145 20.7 17.7-23.8
Female 793 136 18.4 15.7-21.4
Neuter Entire 78 22 28.2 18.6-39.5
Neutered 1119 228 20.4 18.1-22.9
Breed Crossbred 1237 260 21.0 18.8-23.3
Purebred 201 19 9.5 5.4-13.5
Reason for presentation Clinical signs 471 178 37.8 33.4-42.3
Anaesthetic monitoring 425 3 0.7 0.01-2.1
Geriatric health check 40 12 30.0 16.6-46.5
Monitoring of concurrent disease 419 88 21.0 1.7-25.2
Other 5 1 20.0 0.5-71.6
Abbreviation: CI, confidence interval.
a Calculated using exact method
TABLE 3 Clinical investigations performed in hypertensive cats and
clinical signs of hypertension recorded at diagnosis (based on total
282 incident cases)
N %
Blood pressure
measurements
None 61 21.6
At diagnosis only 73 25.9
After diagnosis 148 52.5
Urine protein assessment Urine protein measured 100 35.5
• Urine protein:creatinine ratio 28 9.9
• Urine dipstick 72 25.5
Proteinuria classification Non-proteinuric 68 68.0
Proteinuric 23 23.0
No classification made 9 9.0
Clinical Signs Blind 78 27.7
Retinopathy 132 46.8
• Retinal detachment 80 28.4
• Tortuous vessels 17 6.0
• Retinal hemorrhage 55 19.5
• Hyphema 31 11.0
Neurological signs 44 15.6
• Seizures 8 2.8
• Ataxia 18 6.4
• Behavior change 13 4.6
• Circling 5 1.8
No clinical signs reported 106 37.6
Bold indicates group level with individual investigations or clinical signs
listed below. Cats may have had more than one clinical sign within each
group.
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3.4 | Survival Analysis
Thirty-five cats diagnosed with hypertension had no follow-up.
Twenty-seven cats had <7 days follow-up and 220 cats had ≥7 days
follow-up.. Of the 35 cats with no follow-up, 82.9% (29) were eutha-
nized at the time of diagnosis of hypertension, and the remaining
6 were not presented to the practice again after diagnosis. Of the
27 cats that had <7 days follow-up, 17 (63.0%) were euthanized,
1 (3.7%) died naturally and 9 (33.3%) were censored. The most com-
mon reasons for euthanasia were quality of life (QOL; 35.3%; n = 6),
CKD (23.5%; n = 4) and blindness (11.8%; n = 2). All further analysis
only includes those cats with ≥7 days follow-up. Just over a third
(38.6%; n = 85) of the cats with ≥7 days follow-up were subsequently
lost to follow-up and 130 (59.1%) died during the follow-up period
(until December 31, 2015). Those cats (n = 5) that were alive at the
end of the study period and those lost to follow-up (n = 85) were cen-
sored in the survival analysis. The median follow-up time for those
cats lost to follow-up was 375 days (IQR, 146-772 days). The most
common reasons reported for euthanasia were QOL (16.8%; 37), CKD
(13.6%; 30), and neurological signs (5.9%; 13). For 16 of the
35 (55.2%) cats euthanized at diagnosis, the reason for euthanasia
was recorded as clinical signs related to hypertension. Estimated
median survival time of cats with ≥7 days follow-up was 400 days
(IQR, 147-797; Figure 2). All-cause mortality rate was estimated at
6.57 deaths per 10 hypertensive cat years at risk (95% CI, 5.54-7.81).
The univariable Cox proportional hazard model identified the fol-
lowing variables to be broadly associated with death after hyperten-
sion diagnosis: neuter status, reason for presentation, body condition
score, body weight, number of times blood pressure was measured
after diagnosis, ocular examination, blindness, retinopathy, tortuous
vessels, seizures, behavioral change, proteinuria, UPC, amlodipine,
atenolol, diabetes mellitus, and investigations performed. No cluster-
ing was identified at the veterinary group level.
The final multivariable model included retinal detachment, tortu-
ous vessels, reason for presentation, investigations after diagnosis,
amlodipine use, CKD diagnosis, and diabetes mellitus diagnosis
(Table 4). Cats not receiving amlodipine treatment were at increased
hazard of death (HR, 1.59; 95% CI, 0.98-2.55; P = .06) compared to
those that did receive it but had no dose change, although the differ-
ence was not significant at the 5% level in the multivariable analysis.
Cats that received amlodipine but required a dose change were at
decreased hazard of death (HR, 0.56; 95% CI, 0.36-0.87; P = .01). Cats
that had retinal detachment or tortuous vessels at diagnosis were at
increased hazard of death, as were cats with a diagnosis of CKD or
diabetes mellitus. Cats that were presented for monitoring of concur-
rent disease and cats that had investigations for underlying disease
after diagnosis of hypertension were at decreased hazard of death.
There was no evidence of interaction in the model and the propor-
tional hazard assumption was met. Predictive ability of the model and
model fit was adequate (Harrell’s C, 0.68).
3.5 | Blood pressure and treatment
Cats that received amlodipine treatment alone had significantly higher
blood pressure at diagnosis (median, 210 mm Hg; IQR, 195-232) in
comparison to cats that received benazepril alone (median, 195 mm
Hg; IQR, 185-220; Mann-Whitney P = .03). No difference was found
in blood pressure at diagnosis between cats that received amlodipine
or benazepril alone and amlodipine and benazepril combined.
4 | DISCUSSION
Ours is the first study to determine the frequency with which blood
pressure is measured in general veterinary practice in the UK, showing
that 1 in 75 cats had their blood pressure assessed during the study
period, increasing to just under 1 in 23 of cats ≥9 years. The findings
suggest that blood pressure measurement is not commonly used to
screen cats known to be at risk of developing hypertension (eg, the
aging cat, those with CKD, and those with hyperthyroidism). The most
common reason for measuring blood pressure was because of the
presence of clinical signs compatible with hypertension. Furthermore,
the results of our study suggest a benefit for cats that are screened
for hypertension because they survived longer than those that had
developed clinical signs of hypertension leading to their diagnosis.
Whether early treatment of hypertension in cats that are screened
decreases morbidity and mortality related to hypertension cannot be
determined by this retrospective study. However, prospective experi-
mental studies suggest that by lowering blood pressure, amlodipine
does protect against hypertensive ocular damage.25
Cats with a diagnosis of CKD or hyperthyroidism or apparently
healthy cats ≥9 years also are recommended to have regular blood
pressure measurements because of increased risk of hyperten-
sion.2,6,26 In our study population, just under 24% of cats were
≥9 years of age. Previous research has estimated that 3.6% of cats
have a diagnosis of CKD and 3% of cats have a diagnosis of hyperthy-
roidism in the PCP-attending population.27 This suggests that blood
pressure measurement is not being utilized routinely as a screening
measure in higher risk cats, based on the lower proportion of cats
receiving BPA and having it recommended. This could be because of
FIGURE 2 Kaplan-Meier curve of all-cause mortality of 220 cats
diagnosed with hypertension. Dash indicates censoring of cat.
Estimated median survival time was 400 (interquartile range [IQR],
147-797) days
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the lack of experience, confidence, or training in measuring blood
pressure in cats, and availability of the appropriate equipment in some
practices or reluctance on the part of owners to pay for routine
screening. The awareness of white coat hypertension also may mean
veterinarians are reluctant to perform blood pressure measurements
in a busy clinic because of the lack of confidence in the accuracy of
the result.10 Very few cats <9 years had their blood pressure
assessed. Without a baseline blood pressure measurement, as dis-
cussed in the ACVIM guidelines,6 it may be more difficult for veteri-
narians to assess if there has been an increase in blood pressure,
potentially delaying the diagnosis of hypertension in some cats.
Calculated incidence risk was similar to that previously estimated
from healthy cat populations, but previous studies were conducted on
cats ≥9 years of age.1–3 In our study, most cats that received BPA
were ≥9 years, which may explain the similarities with previous stud-
ies. Blood pressure assessment appears to have been targeted at high
risk cats in our study population (ie, older cats, cats with pre-existing
disease, and cats with clinical signs). Subclinical disease may have
been missed because few cats were diagnosed with hypertension
before clinical signs were present. This may result in the incidence
estimate calculated being an underestimate of the true incidence of
hypertension.
Median blood pressure at diagnosis was within the severe risk
ACVIM category, with most cats having blood pressure of ≥180 mm
Hg at diagnosis. This finding is consistent with most cats showing clin-
ical signs of TOD at diagnosis. Earlier diagnosis of hypertension may
decrease the number of cats presenting with evidence of TOD, as has
been seen in a study that enrolled cats with lower blood pressure at
diagnosis of hypertension,15 which may decrease the morbidity asso-
ciated with the condition. In another study that performed regular
blood pressure measurements longitudinally in initially normotensive
cats, 52% were found to have evidence of TOD at the point at which
they were diagnosed with hypertension,2 lower than the proportion
of cats with TOD at time of diagnosis in our study. Hypertension is
considered to cause harm by resulting in TOD, and decreasing QOL in
these cats.6 Quality of life was found to be decreased in hypertensive
cats before starting treatment in 1 study,15 and QOL was the most
frequently reported reason for euthanasia in our study. Some clinical
signs associated with CKD have been found to negatively impact QOL
of cats with CKD.28 Neurological signs have been reported to be the
6th most common reason for death in cats attending PCP.29 This
observation would all suggest that clinical disease associated with
TOD may decrease QOL in cats. Because all cats diagnosed with dia-
betes mellitus were euthanized, it is possible that the QOL impact on
the cat and owner of this disease influenced the HR calculated in our
study, and that the impact of hypertension on death in these cats is
lower than calculated. Additionally, blood pressure at diagnosis was
not associated with survival. However, an association was identified
between TOD and survival, which suggests that severity of hyperten-
sion (as reflected by evidence of TOD rather than a single blood
pressure measurement made in the clinic) is associated with survival
after diagnosis.
Blood pressure monitoring of cats after diagnosis was limited,
which may mean that control of blood pressure was inadequate in
some cats and did not result in a decrease in blood pressure that
would decrease the cat’s risk of TOD. The UPC was measured in a
minority of cats, despite the association between both UPC at diagno-
sis and the time averaged UPC after treatment and survival after
hypertension diagnosis.8 Primary care veterinarians may not be aware
of this association, or owners may decline to have UPC measured.
The use of urine dipstick tests to assess cat urine for the presence of
protein lacks sensitivity and specificity.24 Cats requiring an increase in
amlodipine dose were found to have significantly higher blood pres-
sure at diagnosis in comparison to those that did not. This finding is in
TABLE 4 Mulitvariable Cox proportional hazard analysis of association with survival (including only cats that had >7 days survival, n = 220)
Variable N Deaths (%) HR 95% CI
P-value
Wald’s test LRT
Retinal detachment No 166 90 (54.2) Reference .01
Yes 54 40 (74.1) 1.71 1.12-2.62 .01
Tortuous vessels No 209 119 (56.9) Reference .008
Yes 11 11 (100.0) 2.67 1.41-5.07 .003
Reason for presentation Clinical signs 123 77 (62.6) Reference .03
Anesthetic monitoring 3 3 (100) 2.61 0.76-9.03 .22
Geriatric health screen 12 6 (50) 0.95 0.40-2.26 .91
Monitoring of concurrent disease 82 44 (53.7) 0.58 0.37-0.89 .01
Investigation after diagnosis No 41 31 (75.6) Reference .0006
Yes 179 99 (55.3) 0.42 0.26-0.68 <.001
Amlodipine No 44 30 (68.2) 1.59 0.98-2.55 .06
Yes - no dose change 116 67 (57.8) Reference .0006
Yes - dose change 60 33 (55) 0.56 0.36-0.87 .01
Concurrent CKD No 101 61 (60.4) Reference .002
Yes 119 69 (58.0) 2.05 1.40-3.22 .002
Concurrent Diabetes Mellitus No 214 124 (57.9) Reference .02
Yes 6 6 (100) 3.31 1.40-7.82 .006
Abbreviations: HR, hazard ratio; CI, confidence interval; LRT, likelihood ratio test.
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agreement with a recent study,16 even though not all cats had a
follow-up blood pressure measurement to ensure adequate blood
pressure control in our study. Because of inadequate monitoring, it
was not possible to investigate the association between blood pres-
sure control and survival after hypertension diagnosis.
Retinal detachment and tortuous vessels identified at diagnosis of
hypertension both were associated with increased hazard of death.
These cats also may have had TOD in other organs, such as the heart,
that may have predisposed them to more life-limiting clinical signs.
The owners of these cats also may have chosen to euthanize them
sooner than cats without these clinical signs because of their per-
ceived decreased QOL. Hypertensive cats that were diagnosed while
being monitored for hypertension associated with a known predispos-
ing disease were at lower hazard of death in comparison to cats that
were diagnosed with hypertension after presentation for clinical signs.
This finding was most likely because of hypertension being diagnosed
earlier in cats being monitored for it, and therefore decreasing the risk
of TOD in these cats. It is also possible that this association with sur-
vival is caused by lead time bias, because cats diagnosed while being
monitored for a pre-existing disease are diagnosed earlier and they
are considered to have had hypertension longer than they would have
had if they were not diagnosed until clinical signs of hypertension
were present. Cats that received investigations for an underlying
cause of their hypertension also had a lower hazard of death in com-
parison to those cats that did not. This is likely associated with the
owners being more proactive in treatment of hypertension in their
cats, and these cats may have had increased monitoring after diagno-
sis of hypertension and therefore better treatment. A dose change in
amlodipine was associated with decreased hazard of death. Cats that
had a dose change of amlodipine had significantly more blood pres-
sure measurements after diagnosis of hypertension in comparison to
cats that did not receive a dose change. It seems most likely that the
association between dose change and survival was related to
improved monitoring after diagnosis and better treatment, because
these cats had blood pressure measurements after diagnosis to iden-
tify the lack of response to amlodipine at the initial dose. It is also pos-
sible that owners who are more committed to monitoring and
treatment of hypertension in their cats are more likely to have uncon-
trolled hypertension identified and that improved survival associated
with dose change is an indirect effect of this vigilance. Proteinuria
was not found to be associated with survival, unlike findings in previ-
ous studies.8 This difference is likely because of the small numbers of
cats that had UPC measured, leading to the study being underpow-
ered to detect this association.
A subgroup analysis was undertaken to see if there were any
associations between blood pressure at diagnosis and treatments
received and between treatments received and average blood pres-
sure after diagnosis. These analyses were performed primarily for
hypothesis-generating purposes. Cats receiving amlodipine treatment
had higher blood pressure at diagnosis than did cats receiving benaze-
pril. This observation may be caused by veterinarians being unwilling
to prescribe amlodipine to cats they perceived to have mild hyperten-
sion “on the cascade” (a UK system for deciding what medicine should
be used for a condition in a particular species30) because, at the time
this study was conducted, amlodipine did not have a product
authorization for cats.30 The preparations of amlodipine available for
human in 2012-2015 required tablets to be divided into much smaller
doses for cats. It also may be that veterinarians were concerned about
potential adverse effects of amlodipine, although it has been shown
recently that amlodipine has no more adverse effects than a pla-
cebo.15 These considerations may explain why some veterinarians
opted to give benazepril to cats with less severe hypertension. No
controlling for confounding was performed in this subgroup analysis,
and unrecognized confounding may be present.
Our study had a number of limitations. It is possible that potential
cases were not identified from the searches because of veterinarians
using different terms in the EPR. This limitation was shown to be of
low significance by a pilot study carried out to informally assess the
sensitivity and specificity of the search terms. The case definition
relied on veterinarians performing a BPA and correctly identifying
hypertension, no minimum blood pressure was required. Also, it was
not possible to validate the techniques used by clinicians, the interpre-
tation of the blood pressure measurement or differentiate between
measurements from Doppler or oscillometric BP machines. This may
mean that some cats were misclassified as hypertensive when they
had white coat hypertension or normotensive when they actually
were hypertensive. It also relied on veterinarians measuring blood
pressure, and so cases may have been missed. The data were not
recorded for research purposes, so there is the possibility of missing
data resulting in misclassification of variables. Not all cats received
follow-up blood pressure measurements, so any analysis of control of
hypertension may be biased or underpowered. There is also the possi-
bility that cats that received follow-up blood pressure measurements
were different in some way from those cats that did not, resulting in
bias. It is possible that some cats lost to follow-up had misclassifica-
tion of variables because of the lack of follow-up in their available
clinical notes. Insurance data were not available for our study. Insur-
ance status may have been a confounder in the survival analysis. A
lack of definitive diagnosis of practitioner-diagnosed cardiac disease
meant that adaptive hypertrophy secondary to hypertension could
not be considered separately in the survival analysis.
Our study highlighted that inadequate blood pressure measure-
ment is performed in cats attending PCP in the UK. Hypertension is
associated with considerable morbidity in this population and limited
monitoring after diagnosis of hypertension occurs. Cats with hyper-
tension diagnosed before associated clinical signs occur have
improved survival, as do cats that have regular blood pressure moni-
toring after diagnosis and institution of treatment. Encouraging more
routine blood pressure monitoring in older cats (≥10 years of age) and
in cats with CKD and hyperthyroidism, before signs of TOD become
apparent, should improve survival and decrease morbidity associated
with hypertension. Encouraging owners and veterinarians to imple-
ment routine blood pressure measurement as part of routine health
screening in healthy cats may allow earlier diagnosis of hypertension
and earlier implementation of treatment. Further research into why
veterinarians do not carry out blood pressure monitoring more rou-
tinely and reasons for limited monitoring after diagnosis of hyperten-
sion would aid in the design of educational programs to improve
owner and veterinarian use of blood pressure measurement in daily
practice. By identifying hypertension early, we may be able to
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decrease associated morbidity and improve survival, thus improving
the health and welfare of cats diagnosed with hypertension in the UK.
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